Hospital

Expert notes that any unease around the use of radiopharmaceuticals is just due to a lack of familiarity with the field.

Training pharmacy technicians to evaluate tasks such as appropriate site of care and plan benefits can reduce the workload for the pharmacist.

Tina Saleh, PharmD, PGY1 specialty pharmacy resident at the University of Illinois Hospital and Health Science System, discusses how oral anticancer agents differ from infusions and how pharmacists can improve tolerability for patients.

Certain areas of chapters written by US Pharmacopeia have evolved since being made official and have become standard best practices today.

Angela Livingood, PharmD, MHA, BCGP, CPHQ, diversion specialist at Novant Health, discusses what drug diversion is and why it is important for pharmacists to be aware of it.

Brooke Looney, PharmD, certified specialty pharmacist in the Oncology Clinic at Vanderbilt Specialty Pharmacy, discusses medication changes and adverse events for patients starting encorafenib and binimetinib.

Shields Health Solutions poster presentations highlight a comprehensive approach to specialty patient care and successful results from an expanded offering of instructional programs.

Nicholas Robert, MD, chief medical officer at Ontada, discussed disparities in biomarker testing and how they are being addressed.

New recommendations provide some harmonization to make it easier for clinicians to lower the barriers to assessing and identifying eligible patients for the pneumococcal vaccine.

COVID-19 vaccine recommendations have parallel tracks for adults and parallel tracks for children broken down into whether an individual is immunocompromised.

Raloxifene hydrochloride (Evista) is indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis.

Kayla Cierniak, PharmD, MS, BCPS, FISMP, medication safety officer in oncology at Seidman Cancer Center discusses the Bar Code Medication Administration and some challenges the initiative faced.

Arpit Mehta, PharmD, MPh, MHA, director of Pharmacy at Allegheny General Hospital, discusses innovations in health-system patient care models to improve patient outcomes.

Katherine Harte, PharmD, a PGY2 ambulatory care pharmacy resident at the Rhode Island Hospital in Providence, Rhode Island, discusses the impact of pharmacist management on SGLT2 inhibitors and GLP-1 receptor agonist utilization in patients with type 2 diabetes mellitus.

Migraines can have a high cost for the health care system overall, with an estimated $1 billion dollars or more spent in indirect and direct costs.

Expert emphasizes that it is important to acknowledge the critical role of pharmacists in overcoming barriers to vaccinations.

Aimee Banks, PharmD, BCPS, MSCS, clinical pharmacist in the Multiple Sclerosis Clinic at Vanderbilt University Medical Center, discusses new hematology, oncology, and autoimmune therapies in the pipeline that pharmacists should be aware of.

Baricitinib (Olumiant) is indicated for the treatment of rheumatoid arthritis and COVID-19 in hospitalized adults.

The new recommendations include 10 key points for managing this type of stroke, including training for home caregivers to improve patients’ quality of life.

Five-year progression-free survival in the CLL14 trial is approximately 63% in the targeted treatment arm, according to new data.

In an analysis of data from 2 patient cohorts included in the phase 2 BYLieve study, investigators found that the data may indicate an increased dependence on the mutant PI3K-α.

Results from a phase 3b study showed that venetoclax combined with azacitidine or decitabine can safely be initiated in a US community-based outpatient setting.

Renin-angiotensin-aldosterone system inhibitors found to reduce the risk of an aneurysm rupture by 18%.

Medication adherence is critical to control the symptoms of congestive heart failure.

The American Society of Health-System Pharmacists’ conference includes educational opportunities that feature the latest products, services, and technology in the industry.

JZP458, a recombinant Erwinia-derived ASNase from a Pseudomonas fluorescens expression platform, was previously approved by the FDA for patients with ALL/LBL who had developed hypersensitivity to Escherichia coli (E. coli)–derived ASNase.

Investigators reported that individuals who completed 10 cycles of lurbinectedin and doxorubicin who then switched to lurbinectedin as a monotherapy tended to have maintained or improved tumor response.

Investigators found that individuals receiving selinexor had a median PFS of 5.7 months compared to 3.8 months for those given the placebo, with a stratification adjusted hazard ratio of 0.70.

The ability to measure GFR would be a significant advancement for clinicians in the United States.

Dosing recommendations for patients requiring ECMO support are unlikely to be supported by high-quality evidence, but are usually extrapolated from the physicochemical characteristics of individual drugs in conjunction with data from pharmacokinetic studies and case reports.